Table 3.
Associations between patient factors and CRRM rates.
| N | CRRM rate | p value | |
|---|---|---|---|
| Age at breast cancer (years) | < 0.001* | ||
| < 45 | 132 | 64 (48.5%) | |
| 45–49 | 109 | 33 (30.3%) | |
| 50–54 | 75 | 18 (24.0%) | |
| 55 + | 70 | 8 (11.4%) | |
| Estimated lifetime risk (%) | < 0.001* | ||
| < 30% | 122 | 17 (13.9%) | |
| 30–39% | 101 | 27 (26.7%) | |
| 40+% | 163 | 79 (48.5%) | |
| Risk category** | < 0.001 | ||
| Moderate | 117 | 17 (14.5%) | |
| High (non-BRCA) | 163 | 47 (28.8%) | |
| BRCA1 | 54 | 29 (53.7%) | |
| BRCA2 | 50 | 30 (60.0%) | |
| Pathology | 0.509 | ||
| IDC | 276 | 84 (30.4%) | |
| ILC | 30 | 9 (30.0%) | |
| Mixed IC | 4 | 1 (25.0%) | |
| Pre-Invasive | 71 | 28 (39.4%) | |
| Size category | 0.793 | ||
| Invasive: 0–19 mm | 212 | 64 (30.2%) | |
| Invasive: 20+ mm | 92 | 29 (31.5%) | |
| In-situ: 0–19 mm | 39 | 14 (35.9%) | |
| In-situ: 20 mm | 24 | 9 (37.5%) | |
| Grade | 0.015 | ||
| Grade 1 | 44 | 6 (13.6%) | |
| Grade 2 | 119 | 36 (30.3%) | |
| Grade 3 | 144 | 52 (36.1%) | |
| Carcinoma in-situ | 71 | 28 (39.4%) | |
| Lymph node status (pathological) | 0.196* | ||
| Negative | 239 | 77 (32.2%) | |
| 1–3 nodes Positive | 72 | 19 (26.4%) | |
| > 3 nodes Positive | 12 | 2 (16.7%) | |
| TNM stage | 0.040* | ||
| Stage 0 | 68 | 28 (41.2%) | |
| Stage 1 | 188 | 61 (32.4%) | |
| Stage 2 | 107 | 30 (28.0%) | |
| Stage 3 | 16 | 3 (18.8%) | |
| Molecular subtype | 0.327 | ||
| Luminal A | 238 | 72 (30.3%) | |
| Luminal B | 10 | 2 (20.0%) | |
| Triple Negative | 89 | 34 (38.2%) | |
| HER2 enriched | 6 | 3 (50.0%) |
Data are reported as N (row %), with p values from Fisher’s exact tests, unless stated otherwise. Bold p values are significant at p < 0.05. *p value from Mann–Whitney U test, as the factor is ordinal. **Excludes N = 1 with both BRCA1 and BRCA2 mutations. IDC invasive ductal carcinoma, ILC Invasive Lobular carcinoma, IC invasive carcinoma.